GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (FRA:CLM) » Definitions » Gross Margin %

Clearside Biomedical (FRA:CLM) Gross Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Clearside Biomedical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Clearside Biomedical's Gross Profit for the three months ended in Dec. 2023 was €5.82 Mil. Clearside Biomedical's Revenue for the three months ended in Dec. 2023 was €5.82 Mil. Therefore, Clearside Biomedical's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Clearside Biomedical's Gross Margin % or its related term are showing as below:

FRA:CLM' s Gross Margin % Range Over the Past 10 Years
Min: 84.63   Med: 90.16   Max: 95.68
Current: 95.68


During the past 11 years, the highest Gross Margin % of Clearside Biomedical was 95.68%. The lowest was 84.63%. And the median was 90.16%.

FRA:CLM's Gross Margin % is ranked better than
94.03% of 737 companies
in the Biotechnology industry
Industry Median: 59.43 vs FRA:CLM: 95.68

Clearside Biomedical had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Clearside Biomedical was 0.00% per year.


Clearside Biomedical Gross Margin % Historical Data

The historical data trend for Clearside Biomedical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Gross Margin % Chart

Clearside Biomedical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 84.60 95.69

Clearside Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.14 - 79.04 83.48 -

Competitive Comparison of Clearside Biomedical's Gross Margin %

For the Biotechnology subindustry, Clearside Biomedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clearside Biomedical's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Clearside Biomedical's Gross Margin % falls into.



Clearside Biomedical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Clearside Biomedical's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=7.2 / 7.543
=(Revenue - Cost of Goods Sold) / Revenue
=(7.543 - 0.325) / 7.543
=95.69 %

Clearside Biomedical's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=5.8 / 5.818
=(Revenue - Cost of Goods Sold) / Revenue
=(5.818 - 0) / 5.818
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Clearside Biomedical  (FRA:CLM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Clearside Biomedical had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Clearside Biomedical Gross Margin % Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clearside Biomedical (FRA:CLM) Business Description

Traded in Other Exchanges
Address
900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical (FRA:CLM) Headlines